ImpediMed Ltd
ASX:IPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ImpediMed Ltd
Other Current Liabilities
ImpediMed Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImpediMed Ltd
ASX:IPD
|
Other Current Liabilities
AU$2.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
4%
|
|
|
Somnomed Ltd
ASX:SOM
|
Other Current Liabilities
AU$5.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Cochlear Ltd
ASX:COH
|
Other Current Liabilities
AU$107.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Other Current Liabilities
AU$549.3k
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Other Current Liabilities
AU$9.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Other Current Liabilities
AU$481.6k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
See Also
What is ImpediMed Ltd's Other Current Liabilities?
Other Current Liabilities
2.5m
AUD
Based on the financial report for Dec 31, 2025, ImpediMed Ltd's Other Current Liabilities amounts to 2.5m AUD.
What is ImpediMed Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
4%
Over the last year, the Other Current Liabilities growth was 28%. The average annual Other Current Liabilities growth rates for ImpediMed Ltd have been -3% over the past three years , -10% over the past five years , and 4% over the past ten years .
